This article has Open Peer Review reports available.
Synchronous lung and gastric cancers successfully treated with carboplatin and pemetrexed: a case report
© Sato et al.; licensee BioMed Central Ltd. 2012
Received: 17 April 2012
Accepted: 22 June 2012
Published: 31 August 2012
Lung and gastric cancers are the first and second leading causes of death from cancer worldwide, and are especially prevalent in Eastern Asia. Relatively few reports are available in relation to the treatment and outcome of synchronous lung and gastric cancers, although there are increasing numbers of patients with these cancers. Efforts to develop more effective drugs for the treatment of synchronous cancers, without serious adverse effects, have been intensifying. Pemetrexed, a multi-targeted antifolate enzyme inhibitor, was approved by the United States Food and Drug Administration as a first-line chemotherapy for advanced non-squamous non-small cell lung cancer in 2007. Although clinical activity against several tumor types of adenocarcinoma, including gastric cancer, has been demonstrated, the efficacy of pemetrexed for gastric cancer remains to be fully evaluated.
We report a case involving a 62-year-old Japanese woman with synchronous locally-advanced poorly-differentiated lung adenocarcinoma and poorly-differentiated gastric adenocarcinoma, containing signet-ring cells distinguished by immunohistochemical profiles. She had been treated with carboplatin and pemetrexed as a first-line chemotherapy for lung cancer, and had achieved partial responses for both lung and gastric cancers. These responses led to a favorable 12-month progression-free survival after the initiation of chemotherapy, and the patient is still alive more than 33 months after diagnosis.
This case suggests a new chemotherapeutic regimen for patients with synchronous multiple primary cancers that have an adenocarcinoma background.
The incidence of synchronous cancers has increased because of the reduced mortality resulting from improved treatments and the development of advanced tools for the early detection of cancerous lesions. Although gastric cancer used to be ranked as the most common cancer, especially in Eastern Asia, recent epidemiological studies have revealed that lung cancer is the leading cause of death from cancer in Japan, exceeding gastric, colorectal and breast cancer in rates of mortality [1, 2]. Thus, more patients with synchronous and metachronous lung and gastric cancers are now encountered. However, few reports are available regarding treatment and outcome, especially in the case of synchronous forms of these cancers. Here, we report on the case of a patient with synchronous non-small cell lung cancer (NSCLC) and early gastric cancer that were successfully treated with carboplatin plus pemetrexed.
In accordance with our patient’s request, cisplatin-containing regimens were not considered due to a requirement for massive hydration and hospitalization associated with this type of therapy. For this reason, treatment was initiated with carboplatin (area under the curve: 5) plus pemetrexed (500mg/m2) as a first-line chemotherapy for the locally advanced lung cancer on the basis of the available phase III clinical trial evidence . Chemoradiotherapy was not chosen as a treatment option because of the requirement for an extended radiation field. The combination of these drugs was tolerated without any grade 3 or 4 adverse events, determined according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. After four cycles of chemotherapy, the primary lung lesion had been reduced in size and judged as a partial response (PR) using the Response Evaluation Criteria in Solid Tumors criteria (Figure 1). Moreover, the primary gastric lesion was macroscopically diminished (Figure 2), although a few signet-ring cells were still found in biopsy specimens. Along with this favorable outcome, our patient received a further four cycles of maintenance monotherapy with pemetrexed (500mg/m2) every three weeks, resulting in stable disease status.
Four months after the last maintenance therapy, chest CT and gastrointestinal tract endoscopy revealed re-growth of the primary lung lesion and recurrence of the mucosal lesion in the stomach, resulting in progressive disease with a 12-month progression-free survival. As a second-line chemotherapy, docetaxel (60mg/m2) was initiated and achieved a PR for the lung cancer after three cycles of treatment, although it caused grade 4 leukopenia and neutropenia according to the CTCAE criteria, even after a 20% reduction in dose. After six cycles of treatment, the gastric lesion was evaluated as slowly progressive (still judged as having stable disease status), while the lung lesion was still diminished. A total of nine cycles of docetaxel treatment slowed progressive disease in the case of both the lung cancer in the enlarged mediastinal LNs and the gastric cancer in the extended gastric mucosal lesion. Following chemotherapy with weekly irinotecan (100mg/m2) as a third-line chemotherapy, our patient also exhibited grade 4 leukopenia and neutropenia. However, the treatment was successfully administered in the case of the lung cancer, with reduced mediastinal LNs, and was judged as a PR after four cycles of treatment. However, there was no response to this chemotherapy regimen in the case of the gastric cancer, with the disease showing further progression. Our patient is still alive 33 months after diagnosis, and further chemotherapy is planned including oral fluoropyrimidine S-1 as a gastric cancer-oriented therapy.
The incidence of synchronous cancers of the lung and stomach has been reported as being 0.71% and 0.72% in Korean and Japanese patients, respectively [4, 5]. Of these patients, about 50% received only radiotherapy or supportive care, mainly due to the advanced stage of the lung cancer, resulting in one- and two-year survival rates of 50% and 32.4%, respectively . Pemetrexed is a recently developed antifolate drug shown to prolong survival time in patients with non-squamous NSCLC and to have a favorable toxicity profile, and was tolerated even in patients who had received it as a third- or further-line treatment . Although activity of pemetrexed against several breast, gastric, pancreatic and colorectal adenocarcinoma cell lines has been reported , only a limited number of phase I or II studies involving chemotherapy including pemetrexed have been carried out in patients with gastric cancer; response rates ranged from 23% to 36% [8, 9]. In Japan, there is only one case report demonstrating the efficacy of carboplatin plus pemetrexed in patients with gastric cancer . Our case showed the efficacy of docetaxel or irinotecan monotherapy in non-squamous NSCLC, but not in gastric adenocarcinoma. Taken together, we may consider that pemetrexed plus carboplatin has greater potential efficacy and lower adverse effects compared with docetaxel or irinotecan monotherapy in the treatment of advanced gastric cancer, even when it is poorly differentiated.
Findings from our case suggest a new chemotherapeutic regimen with low adverse effects for patients with synchronous multiple primary cancers with an adenocarcinoma background.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We thank the nursing staff of Yokohama City University Hospital.
- Inoue M, Tsugane S: Epidemiology of gastric cancer in Japan. Postgrad Med. 2005, 81 (957): 419-424. 10.1136/pgmj.2004.029330.View ArticleGoogle Scholar
- Nakaya N, Goto K, Saito-Nakaya K, Inagaki M, Otani T, Akechi T, Nagai K, Hojo F, Uchitomi Y, Tsugane S, Nishiwaki Y: The lung cancer database project at the National Cancer Center, Japan: study design, corresponding rate and profiles of cohort. Jpn J Clin Oncol. 2006, 36 (5): 280-284. 10.1093/jjco/hyl015.View ArticlePubMedGoogle Scholar
- Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S: Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009, 27 (19): 3217-3224. 10.1200/JCO.2008.20.9114.View ArticlePubMedGoogle Scholar
- Bae JS, Lee JH, Ryu KW, Kim YW, Bae JM: Characteristics of synchronous cancers in gastric cancer patients. Cancer Res Treat. 2006, 38 (1): 25-29. 10.4143/crt.2006.38.1.25.View ArticlePubMedPubMed CentralGoogle Scholar
- Kurishima K, Satoh H, Kagohashi K, Homma S, Nakayama H, Ohara G, Ishikawa H, Hizawa N: Patients with lung cancer with metachronous or synchronous gastric cancer. Clin Lung Cancer. 2009, 10 (6): 422-425. 10.3816/CLC.2009.n.079.View ArticlePubMedGoogle Scholar
- Sun JM, Lee KW, Kim JH, Kim YJ, Yoon HI, Lee JH, Lee CT, Lee JS: Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Jpn J Clin Oncol. 2009, 39 (1): 27-32.View ArticlePubMedGoogle Scholar
- Adjei AA: Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res. 2004, 10 (12 Pt 2): 4276s-4280s.View ArticlePubMedGoogle Scholar
- Celio L, Sternberg CN, Labianca R, La Torre I, Amoroso V, Barone C, Pinotti G, Cascinu S, Di Costanzo F, Cetto GL, Bajetta E: Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Ann Oncol. 2009, 20 (6): 1062-1067. 10.1093/annonc/mdn766.View ArticlePubMedGoogle Scholar
- Chen JS, Chao Y, Bang YJ, Roca E, Chung HC, Palazzo F, Kim YH, Myrand SP, Mullaney BP, Shen LJ, Linn C: A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. Anticancer Drugs. 2010, 21 (8): 777-784. 10.1097/CAD.0b013e32833cfbca.View ArticlePubMedGoogle Scholar
- Muto O, Munakata M, Iino C, Sakata Y: Successful treatment of gastric adenocarcinoma in a Meckel’s diverticulum with pemetrexed plus carboplatin. Jpn J Clin Oncol. 2010, 40 (11): 1110-1112. 10.1093/jjco/hyq092.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.